AbbVie is in advanced talks to buy Revolution Medicines, a cancer drug company. The news pushed Revolution Medicines shares sharply higher. Investors see the deal as a growth move for AbbVie’s cancer business. The possible acquisition supports AbbVie’s plan to replace revenue lost after Humira patents expired and strengthen its future drug pipeline.